Company intelligence / Profile preview

NeuroActiva, Inc.

California, United Statesneuroactiva.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Completed Phase 2a trials for NA-831 (Traneurocin) with 56 patients and planned a 156-patient Phase 2b study. The company presented Phase 2a data in July (year not specified) and was planning to start a Phase 2b study (NCT03538522).

Therapeutic areas: NeurologyInfectious Diseases
Modalities: Small molecules
Industry: Biotech

Drug pipeline

5 assets

traneurocin

Phase 2

Indications: Alzheimer's disease

4 more assets in the full pipeline.

Request access →

Partnerships

Was seeking large pharma partnership (as of 2018)

Beyond the preview

Go deeper on NeuroActiva, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NeuroActiva, Inc..

Explore the full profile